Melanoma Clinical Trials in Tennessee

Showing 81-100 of 285 trials

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

NCT06398418

The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.

Solid Tumor, AdultSolid TumorMelanoma+3 more

Rise Therapeutics LLC33 participantsStarted Aug 2025

Nashville, Tennessee, United States

COMPLETEDPhase 129 miles

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

NCT04772989

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Advanced Solid TumorNon Small Cell Lung Cancer (NSCLC)Melanoma+7 more

Arcus Biosciences, Inc.94 participantsStarted Mar 2021

Los Angeles, California, United States • Jacksonville, Florida, United States • Goshen, Indiana, United States +19 more locations

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Melanoma Trials in Other Cities

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Tranexamic Acid in Nasal Mohs Reconstruction

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

MGC018 With or Without MGA012 in Advanced Solid Tumors

A Study to Investigate LYL845 in Adults With Solid Tumors

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Other Conditions in Tennessee